Cesium carbonate → 5-(2,4-dimethoxybenzyl)-7-(2-ethoxy-4-methylpyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one
反応式
[CH3:1][O:2][C:3]1[CH:32]=[C:31]([O:33][CH3:34])[CH:30]=[CH:29][C:4]=1[CH2:5][N:6]1[C:15]2[CH:14]=[C:13](B(O)O)[CH:12]=[CH:11][C:10]=2[C:9]2[N:19]([CH:22]3[CH2:27][CH2:26][O:25][CH2:24][CH2:23]3)[N:20]=[CH:21][C:8]=2[C:7]1=[O:28].FC1C=C(C2C(OC)=NC(C)=CC=2C)C=CC=1C1N(C2CCOCC2)N=CC=1C(OCC)=O.Br[C:69]1[C:70]([O:76][CH2:77][CH3:78])=[N:71][CH:72]=[CH:73][C:74]=1[CH3:75].C(=O)([O-])[O-].[Cs+].[Cs+]>O1CCOCC1.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.O>[CH3:1][O:2][C:3]1[CH:32]=[C:31]([O:33][CH3:34])[CH:30]=[CH:29][C:4]=1[CH2:5][N:6]1[C:15]2[CH:14]=[C:13]([C:69]3[C:70]([O:76][CH2:77][CH3:78])=[N:71][CH:72]=[CH:73][C:74]=3[CH3:75])[CH:12]=[CH:11][C:10]=2[C:9]2[N:19]([CH:22]3[CH2:27][CH2:26][O:25][CH2:24][CH2:23]3)[N:20]=[CH:21][C:8]=2[C:7]1=[O:28]参加物
反応物 4
生成物 1
試薬・触媒・溶媒 3
実験手順
[5-(2,4-dimethoxybenzyl)-4-oxo-1-(tetrahydro-2H-pyran-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinolin-7-yl]boronic acid obtained in Preparation Example 1 (70 mg) was dissolved in 1,4-dioxane (4 mL). 3-bromo-2-ethoxy-4-methylpyridine obtained in Preparation Example 44 (49 mg), Pd(PPh3)4 (8.7 mg), cesium carbonate (148 mg) and water (1 mL) were added to the solution, and the mixture was reacted using a microwave reactor at 130° C. for two hours. The reaction mixture was returned to room temperature and then partitioned by adding ethyl acetate. The organic layer was washed with brine and then dried over magnesium sulfate. The desiccant was removed by filtration, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate/n-heptane, 30% to 50% to 80%) to give 5-(2,4-dimethoxybenzyl)-7-(2-ethoxy-4-methylpyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one (55 mg). The 5-(2,4-dimethoxybenzyl)-7-(2-ethoxy-4-methylpyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one (55 mg) was dissolved in TFA (1 mL), and the mixture was stirred at 65° C. for two hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The resulting residue was neutralized by adding a saturated aqueous sodium bicarbonate solution. The aqueous solution was extracted with DCM. The organic layer was dried over anhydrous magnesium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate/n-heptane, 50% to 70% to 80% to 100%) to give the title compound (17 mg).
後処理
- additionwere added to the solution
- customthe mixture was reacted
- customat 130° C.
- customfor two hours
- customwas returned to room temperature
- custompartitioned
- additionby adding ethyl acetate
- washThe organic layer was washed with brine
- dry with materialdried over magnesium sulfate
- customThe desiccant was removed by filtration
- concentrationthe filtrate was concentrated under reduced pressure
- customThe resulting residue was purified by silica gel column chromatography (ethyl acetate/n-heptane, 30% to 50% to 80%)
出典と根拠
- ORDレコード
- ord-25ccd86e4e9f490dba1b1f493a357c75
- 出典データセット
- uspto-grants-2013_10
- 特許番号
- US08563565B2
反応ノート
読み込み中…